Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.55 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581749 | 0.95 | OPRM1 (0.51) | OPRM1OPRK1OPRL1OPRD1CYP46A1 | |
| SCHEMBL795975 | 0.84 | ALDH1A1 (0.56) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL1427539 | 0.83 | CA12 (0.57) | OPRM1OPRK1OPRL1OPRD1DRD2 | |
| SCHEMBL5368030 | 0.83 | CYP46A1 (0.41) | OPRM1OPRK1OPRL1OPRD1CYP46A1 | |
| SCHEMBL2229509 | 0.83 | MEN1 (0.62) | OPRM1OPRK1OPRL1OPRD1SMN1; SMN2 | |
| SCHEMBL4725181 | 0.83 | OPRM1 (0.55) | OPRM1OPRK1OPRL1OPRD1SMN1; SMN2 | |
| SCHEMBL16874836 | 0.82 | OPRM1 (0.59) | OPRM1OPRK1OPRL1OPRD1SMN1; SMN2 | |
| SCHEMBL5376169 | 0.82 | POLB (0.46) | OPRM1OPRK1OPRL1OPRD1CYP46A1 | |
| SCHEMBL5373048 | 0.81 | OPRM1 (0.60) | OPRM1OPRK1OPRL1OPRD1CYP46A1 | |
| SCHEMBL14372230 | 0.81 | OPRM1 (0.47) | OPRM1OPRK1OPRL1OPRD1CYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | OPRM1 3770/4885OPRK1 3177/4885OPRL1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.